Phase II study of doxercalciferol for the treatment of myelodysplastic syndrome

Adam Petrich; Brad Kahl; Howard Bailey; Kyungmann Kim; Nancy Turman; Mark Juckett

doi:10.1080/10428190701713648

Phase II study of doxercalciferol for the treatment of myelodysplastic syndrome

Adam Petrich, Brad Kahl, Howard Bailey, Kyungmann Kim, Nancy Turman, Mark Juckett

Research output: Contribution to journal › Article › peer-review

25 Scopus citations

Abstract

We conducted a phase II trial of doxercalciferol, a vitamin D2 analogue, in 15 patients with MDS. Each received doxercalciferol 12.5μg orally daily for 12 weeks. Nine of 15 patients completed the prescribed course and of these, six had stable disease. No patient had a response (IWG criteria) and overall eight patients experienced progressive disease while on therapy. Two patients with chronic myelomonocytic leukemia (CMML) had a marked rise in monocytes on study. Overall the treatment was well tolerated. One patient was removed from study due to hypercalcemia. We conclude that short-term treatment with doxercalciferol has limited activity in patients with MDS.

Original language	English (US)
Pages (from-to)	57-61
Number of pages	5
Journal	Leukemia and Lymphoma
Volume	49
Issue number	1
DOIs	https://doi.org/10.1080/10428190701713648
State	Published - Jan 2008
Externally published	Yes

Keywords

Doxercalciferol
Myelodysplastic syndrome
Phase II study

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access

10.1080/10428190701713648

OpenUrl availability

Full text

Cite this

@article{33598f4dc6064806a53678a21d537422,

title = "Phase II study of doxercalciferol for the treatment of myelodysplastic syndrome",

abstract = "We conducted a phase II trial of doxercalciferol, a vitamin D2 analogue, in 15 patients with MDS. Each received doxercalciferol 12.5μg orally daily for 12 weeks. Nine of 15 patients completed the prescribed course and of these, six had stable disease. No patient had a response (IWG criteria) and overall eight patients experienced progressive disease while on therapy. Two patients with chronic myelomonocytic leukemia (CMML) had a marked rise in monocytes on study. Overall the treatment was well tolerated. One patient was removed from study due to hypercalcemia. We conclude that short-term treatment with doxercalciferol has limited activity in patients with MDS.",

keywords = "Doxercalciferol, Myelodysplastic syndrome, Phase II study",

author = "Adam Petrich and Brad Kahl and Howard Bailey and Kyungmann Kim and Nancy Turman and Mark Juckett",

year = "2008",

month = jan,

doi = "10.1080/10428190701713648",

language = "English (US)",

volume = "49",

pages = "57--61",

journal = "Leukemia and Lymphoma",

issn = "1042-8194",

publisher = "Informa Healthcare",

number = "1",

}

TY - JOUR

T1 - Phase II study of doxercalciferol for the treatment of myelodysplastic syndrome

AU - Petrich, Adam

AU - Kahl, Brad

AU - Bailey, Howard

AU - Kim, Kyungmann

AU - Turman, Nancy

AU - Juckett, Mark

PY - 2008/1

Y1 - 2008/1

N2 - We conducted a phase II trial of doxercalciferol, a vitamin D2 analogue, in 15 patients with MDS. Each received doxercalciferol 12.5μg orally daily for 12 weeks. Nine of 15 patients completed the prescribed course and of these, six had stable disease. No patient had a response (IWG criteria) and overall eight patients experienced progressive disease while on therapy. Two patients with chronic myelomonocytic leukemia (CMML) had a marked rise in monocytes on study. Overall the treatment was well tolerated. One patient was removed from study due to hypercalcemia. We conclude that short-term treatment with doxercalciferol has limited activity in patients with MDS.

AB - We conducted a phase II trial of doxercalciferol, a vitamin D2 analogue, in 15 patients with MDS. Each received doxercalciferol 12.5μg orally daily for 12 weeks. Nine of 15 patients completed the prescribed course and of these, six had stable disease. No patient had a response (IWG criteria) and overall eight patients experienced progressive disease while on therapy. Two patients with chronic myelomonocytic leukemia (CMML) had a marked rise in monocytes on study. Overall the treatment was well tolerated. One patient was removed from study due to hypercalcemia. We conclude that short-term treatment with doxercalciferol has limited activity in patients with MDS.

KW - Doxercalciferol

KW - Myelodysplastic syndrome

KW - Phase II study

UR - http://www.scopus.com/inward/record.url?scp=38549145862&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38549145862&partnerID=8YFLogxK

U2 - 10.1080/10428190701713648

DO - 10.1080/10428190701713648

M3 - Article

C2 - 18203012

AN - SCOPUS:38549145862

SN - 1042-8194

VL - 49

SP - 57

EP - 61

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

IS - 1

ER -

Phase II study of doxercalciferol for the treatment of myelodysplastic syndrome

Abstract

Keywords

UN SDGs

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this